Literature DB >> 30094660

Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.

Shaoning Wang1,2, Shihui Yu2,3, Yuwei Lin4, Peizhi Zou2, Guihong Chai2, Heidi H Yu4, Hasini Wickremasinghe4, Nivedita Shetty2, Junhong Ling1,2, Jian Li4, Qi Tony Zhou5.   

Abstract

PURPOSE: This study aims to develop liposomal formulations containing synergistic antibiotics of colistin and ciprofloxacin for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa.
METHODS: Colistin (Col) and ciprofloxacin (Cip) were co-encapsulated in anionic liposomes by ammonium sulfate gradient. Particle size, encapsulation efficiency, in vitro drug release and in vitro antibiotic activities were evaluated.
RESULTS: The optimized liposomal formulation has uniform sizes of approximately 100 nm, with encapsulation efficiency of 67.0% (for colistin) and 85.2% (for ciprofloxacin). Incorporation of anionic lipid (DMPG) markedly increased encapsulation efficiency of colistin (from 5.4 to 67.0%); however, the encapsulation efficiency of ciprofloxacin was independent of DMPG ratio. Incorporation of colistin significantly accelerated the release of ciprofloxacin from the DMPG anionic liposomes. In vitro release of ciprofloxacin and colistin in the bovine serum for 2 h were above 70 and 50%. The cytotoxicity study using A549 cells showed the liposomal formulation is as non-toxic as the drug solutions. Liposomal formulations of combinations had enhanced in vitro antimicrobial activities against multidrug resistant P. aeruginosa than the monotherapies.
CONCLUSIONS: Liposomal formulations of two synergistic antibiotics was promising against multidrug resistant P. aeruginosa infections.

Entities:  

Keywords:  Pseudomonas aeruginosa; antimicrobial activities; ciprofloxacin; colistin; cytotoxicity; in vitro release; liposome

Mesh:

Substances:

Year:  2018        PMID: 30094660      PMCID: PMC6122860          DOI: 10.1007/s11095-018-2464-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  42 in total

1.  Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled β-casein micelles.

Authors:  Michal Bachar; Amitai Mandelbaum; Irina Portnaya; Hadas Perlstein; Simcha Even-Chen; Yechezkel Barenholz; Dganit Danino
Journal:  J Control Release       Date:  2012-01-14       Impact factor: 9.776

2.  Colistin dosing and nephrotoxicity in a large community teaching hospital.

Authors:  C Andrew Deryke; Amanda J Crawford; Nizam Uddin; Mark R Wallace
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

3.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

4.  Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.

Authors:  Phillip J Bergen; Jurgen B Bulitta; Alan Forrest; Brian T Tsuji; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

5.  In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate.

Authors:  Tejas R Desai; Gregory J Tyrrell; Tina Ng; Warren H Finlay
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

6.  Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.

Authors:  Yu-Wei Lin; Qi Tony Zhou; Soon-Ee Cheah; Jinxin Zhao; Ke Chen; Jiping Wang; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

7.  Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies.

Authors:  Stephanie J Wallace; Roger L Nation; Jian Li; Ben J Boyd
Journal:  J Pharm Sci       Date:  2013-03-21       Impact factor: 3.534

Review 8.  Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.

Authors:  Tony Velkov; Kade D Roberts; Roger L Nation; Philip E Thompson; Jian Li
Journal:  Future Microbiol       Date:  2013-06       Impact factor: 3.165

9.  Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries.

Authors:  Pritesh P Jain; Regina Leber; Chandran Nagaraj; Gerd Leitinger; Bernhard Lehofer; Horst Olschewski; Andrea Olschewski; Ruth Prassl; Leigh M Marsh
Journal:  Int J Nanomedicine       Date:  2014-07-07

10.  Tuning Ciprofloxacin Release Profiles from Liposomally Encapsulated Nanocrystalline Drug.

Authors:  David Cipolla; Huiying Wu; Simon Eastman; Tom Redelmeier; Igor Gonda; Hak-Kim Chan
Journal:  Pharm Res       Date:  2016-07-20       Impact factor: 4.200

View more
  12 in total

1.  Simultaneous Particle Size Reduction and Homogeneous Mixing to Produce Combinational Powder Formulations for Inhalation by the Single-Step Co-Jet Milling.

Authors:  Junhong Ling; Sharad Mangal; Heejun Park; Shaoning Wang; Alex Cavallaro; Qi Tony Zhou
Journal:  J Pharm Sci       Date:  2019-05-18       Impact factor: 3.534

2.  Nanomedicines for Infectious Diseases.

Authors:  Admire Dube
Journal:  Pharm Res       Date:  2019-03-11       Impact factor: 4.200

3.  Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model.

Authors:  Guihong Chai; Heejun Park; Shihui Yu; Fanfan Zhou; Jian Li; Qingguo Xu; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2019-08-12       Impact factor: 5.875

4.  Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa.

Authors:  Shihui Yu; Xiaohui Pu; Maizbha Uddin Ahmed; Heidi H Yu; Tarun Tejasvi Mutukuri; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2021-10-06       Impact factor: 5.875

5.  Inhalable Nanocomposite Microparticles with Enhanced Dissolution and Superior Aerosol Performance.

Authors:  Chune Zhu; Jianting Chen; Shihui Yu; Chailu Que; Lynne S Taylor; Wen Tan; Chuanbin Wu; Qi Tony Zhou
Journal:  Mol Pharm       Date:  2020-07-24       Impact factor: 4.939

Review 6.  Emerging therapies against infections with Pseudomonas aeruginosa.

Authors:  Burkhard Tümmler
Journal:  F1000Res       Date:  2019-08-07

Review 7.  Polymyxin Delivery Systems: Recent Advances and Challenges.

Authors:  Natallia V Dubashynskaya; Yury A Skorik
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-29

8.  Polypeptide Self-Assembled Nanoparticles as Delivery Systems for Polymyxins B and E.

Authors:  Dmitrii Iudin; Natalia Zashikhina; Elena Demyanova; Viktor Korzhikov-Vlakh; Elena Shcherbakova; Roman Boroznjak; Irina Tarasenko; Natalya Zakharova; Antonina Lavrentieva; Yury Skorik; Evgenia Korzhikova-Vlakh
Journal:  Pharmaceutics       Date:  2020-09-11       Impact factor: 6.321

Review 9.  The Building Blocks of Antimicrobial Resistance in Pseudomonas aeruginosa: Implications for Current Resistance-Breaking Therapies.

Authors:  R Frèdi Langendonk; Daniel R Neill; Joanne L Fothergill
Journal:  Front Cell Infect Microbiol       Date:  2021-04-16       Impact factor: 5.293

Review 10.  Antimicrobial Activity Enhancers: Towards Smart Delivery of Antimicrobial Agents.

Authors:  Mariusz Skwarczynski; Sahra Bashiri; Ye Yuan; Zyta M Ziora; Osama Nabil; Keita Masuda; Mattaka Khongkow; Natchanon Rimsueb; Horacio Cabral; Uracha Ruktanonchai; Mark A T Blaskovich; Istvan Toth
Journal:  Antibiotics (Basel)       Date:  2022-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.